Document is current

Article History

Accepted: 17 August 2022

First Online: 19 September 2022

Declarations

:

: The authors did not receive support from any organization for the submitted work.

: TF, FDM, DN, and DVW have no relevant financial or non-financial interests to disclose. SAJ has received research support from the ALS association. JDB reports advisory board fees from Biogen, Clene Nanomedicine, MT Pharma of America, MT Pharma Holdings of America, Janssen, Sawai, and Regeneron. He reports research funding from Amylyx, Brainstorm Cell Therapeutics, Biogen, MT Pharma of America, MT Pharma Holdings of America, Alexion, Rapa Therapeutics, Transposon, ALS Association, Muscular Dystrophy Association, ALS One, Tambourine, ALS Finding a Cure. He was paid an honorarium for speaking on an educational program for Projects In Knowledge. SP reports research grants from Amylyx Therapeutics, Revalesio Corporation, UCB/Ra Pharma, Biohaven, Clene, Prilenia, Seelos, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association, Tambourine and reports personal consulting fees from Orion, Medscape, and Cytokinetics.

: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

: SAJ—drafting of the manuscript; data acquisition, analysis, and interpretation; critical revision of the manuscript for important intellectual content. TF—drafting of the manuscript; data acquisition, analysis, and interpretation; critical revision of the manuscript for important intellectual content. FM—initial drafting of manuscript; data acquisition, analysis, and interpretation; critical revision of the manuscript for important intellectual content. DN—analysis and interpretation of the data, critical revision of the manuscript for important intellectual content. DW—analysis and interpretation of the data, critical revision of the manuscript for important intellectual content. JDB—critical revision of the manuscript for important intellectual content. SP—Conception and planning, critical revision of the manuscript for important intellectual content. All authors have read and approved the final manuscript and agree to be accountable for the work.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.